AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.
Authors
Lillian, SDe Bono, J
Higano, C
Shapiro, G
Brugger, W
Mitchell, P
Colebrook, S
Klinowska, T
Barry, S
Dean, Emma J
Martin-Mills, J
Wisinski, K
Moorthy, G
Mills, J
Cruzalegui, F
Tolaney, S
Lang, J
Jose De Miquel Luken, M
Kunar, R
Chatta, G
Affiliation
Princess Margaret Hospital, Oncology, Toronto, CanadaIssue Date
2016-12
Metadata
Show full item recordCitation
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate. 2016, 69 (Suppl 1):S19 European Journal of CancerJournal
European Journal of CancerDOI
10.1016/S0959-8049(16)32637-5Additional Links
http://linkinghub.elsevier.com/retrieve/pii/S0959804916326375Type
Meetings and ProceedingsLanguage
enISSN
09598049ae974a485f413a2113503eed53cd6c53
10.1016/S0959-8049(16)32637-5